Department of Radiology, Binzhou People's Hospital, Binzhou, China.
Department of Interventional Radiology, Binzhou People's Hospital, Binzhou, China.
Minim Invasive Ther Allied Technol. 2022 Apr;31(4):525-530. doi: 10.1080/13645706.2020.1871371. Epub 2021 Jan 12.
To evaluate the efficacy of stent-in-stent (SIS) and side-by-side (SBS) bilateral stenting for treating malignant hilar biliary obstruction (MHBO).
Relevant studies in Pubmed, Embase, and Cochrane Library were identified through June 2020. This meta-analysis was conducted using RevMan v5.3, using relevant endpoint data relating to clinical and technical success, complications, stent dysfunction, and overall survival (OS) rates extracted from these studies.
We identified six relevant studies which included 315 MHBO patients treated with either SBS ( = 161) or SIS bilateral ( = 154) stenting. We saw no significant difference between these two groups with respect to clinical success (OR: 1.07; 95% CI: 0.46, 2.49, = .87), complication (HR: 0.12; 95% CI: -0.04, 0.27, = .15), stent dysfunction (OR: 0.68; 95% CI: 0.42, 1.10, = .11), or OS (HR: 0.97; 95% CI: 0.82, 1.16, = .74). However, the SBS group exhibited significantly lower technical success rates (OR: 6.55; 95% CI: 1.10, 38.83, = .04). Significant heterogeneity was only detected for the endpoint of complication rates ( = 60%).
These results suggest that SIS bilateral stenting yields better rates of technical success than does SBS bilateral stenting in MHBO patients.
评估支架内支架(SIS)和并排(SBS)双侧支架治疗恶性肝门胆管梗阻(MHBO)的疗效。
通过 2020 年 6 月在 Pubmed、Embase 和 Cochrane Library 中检索相关研究。本 meta 分析使用 RevMan v5.3 进行,使用从这些研究中提取的与临床和技术成功率、并发症、支架功能障碍和总生存率(OS)相关的相关终点数据。
我们确定了六项相关研究,共纳入 315 例 MHBO 患者,分别接受 SBS(n=161)或 SIS 双侧(n=154)支架治疗。我们发现这两组患者在临床成功率(OR:1.07;95%CI:0.46,2.49,P=0.87)、并发症(HR:0.12;95%CI:-0.04,0.27,P=0.15)、支架功能障碍(OR:0.68;95%CI:0.42,1.10,P=0.11)或 OS(HR:0.97;95%CI:0.82,1.16,P=0.74)方面无显著差异。然而,SBS 组的技术成功率明显较低(OR:6.55;95%CI:1.10,38.83,P=0.04)。仅并发症发生率的终点检测到显著异质性(I²=60%)。
这些结果表明,与 SBS 双侧支架相比,SIS 双侧支架治疗 MHBO 患者的技术成功率更高。